Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.51 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.51 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.47 |
| ▸ | QPCT | Q16769 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11167746 | 0.96 | MAPT (0.55) | QPCTMAPTUSP2ALDH1A1LMNA | |
| SCHEMBL11166971 | 0.90 | L3MBTL1 (0.54) | MAPTUSP2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11184745 | 0.89 | DRD2 (0.51) | QPCTMAPTUSP2ALDH1A1LMNA | |
| SCHEMBL11163271 | 0.87 | HTR1A (0.52) | QPCTMAPTUSP2ALDH1A1LMNA | |
| SCHEMBL11165829 | 0.85 | DRD2 (0.62) | QPCTMAPTUSP2ALDH1A1LMNA | |
| SCHEMBL11157326 | 0.85 | ALDH1A1 (0.54) | QPCTMAPTUSP2ALDH1A1LMNA | |
| SCHEMBL11173613 | 0.84 | MCHR1 (0.66) | QPCTMAPTUSP2ALDH1A1LMNA | |
| SCHEMBL11198528 | 0.84 | ALDH1A1 (0.60) | QPCTMAPTUSP2ALDH1A1LMNA | |
| SCHEMBL11176687 | 0.83 | MCHR1 (0.60) | QPCTMAPTUSP2ALDH1A1LMNA | |
| SCHEMBL11167178 | 0.83 | HTR7 (0.56) | QPCTMAPTUSP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4413006-A | N-Aryl-N-phenoxy-alkyl-piperazine compounds useful in decreasing intracranial pressure | TANABE SEIYAKU CO., LTD. (JP) | 1983-11-01 | — | — | US | disclosed |
| EP-0034284-A2 | Piperazine derivative, processes for preparing the same and therapeutic compositions containing it | Tanabe Seiyaku Co., Ltd. (JP) | 1981-08-26 | — | — | EP | disclosed |